Novel Antibiotic for Resistant Bacteria gets a €22M Push from Key Investors

16/06/2016 - 3 minutes

Allecra Therapeutics has raised €22M in its Series B round from some key investors. The money will back the Phase II trials for a new broad-spectrum antibiotic for resistant bacteria. 

allecra_therapeutics_antibiotic_resistance_beta_lactamaseThe development of antibiotic resistance in bacteria has been one of the key concerns of healthcare authorities for quite some time. The World Health Organisation estimates that as of 2050, over 10 million people will die every year from antibiotic resistance, more than from cancer.

Developing new antibiotics, which tackle the mechanisms of resistance in bacteria, is the goal of Allecra Therapeutics. The company was founded in 2013 with a €15M Series A and is located in the Rhine region, having bases in Lörrach (Germany) and Saint Louis (France).

Allecra has now raised an additional €22M Series B round led by a new investor – Delos Capital (US). Previous investors also participated, including EMBL Ventures (the investment arm of the European Molecular Biology Laboratory), Edmond de Rothschild and Forbion (both on our list of top European VCs).

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member